

## Anti-*Helicobacter pylori* Activity of the Methanolic Extract of *Geum iranicum* and its Main Compounds

Somayeh Shahani<sup>a</sup>, Hamid R. Monsef-Esfahani<sup>a</sup>, Soodabeh Saeidnia<sup>b</sup>, Parastoo Saniee<sup>c</sup>, Farideh Siavoshi<sup>c</sup>, Alireza Foroumadi<sup>d</sup>, Nasrin Samadi<sup>c</sup>, and Ahmad R. Gohari<sup>b,\*</sup>

<sup>a</sup> Department of Pharmacognosy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

<sup>b</sup> Medicinal Plants Research Center, Tehran University of Medical Sciences, Tehran, P. O. Box 14155-6451, Iran. Fax: +98-21-64122330. E-mail: goharii@tums.ac.ir

<sup>c</sup> Microbiology Department, Faculty of Sciences, University of Tehran, Tehran, Iran

<sup>d</sup> Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran

<sup>e</sup> Department of Drug and Food Control, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran

\* Author for correspondence and reprint requests

Z. Naturforsch. **67c**, 172–180 (2012); received May 30, 2011/January 14, 2012

*Geum iranicum* Khatamsaz, belonging to the Rosaceae family, is an endemic plant of Iran. The methanol extract of the roots of this plant showed significant activity against one of the clinical isolates of *Helicobacter pylori* which was resistant to metronidazole. The aim of this study was the isolation and evaluation of the major compounds of *G. iranicum* effective against *H. pylori*. The compounds were isolated using various chromatographic methods and identified by spectroscopic data (<sup>1</sup>H and <sup>13</sup>C NMR, HMQC, HMBC, EI-MS). An antimicrobial susceptibility test was performed employing the disk diffusion method against clinical isolates of *H. pylori* and a micro dilution method against several Gram-positive and Gram-negative bacteria; additionally the inhibition zone diameters (IZD) and minimum inhibitory concentrations (MIC) values were recorded. Nine compounds were isolated: two triterpenoids, uvaol and niga-ichigoside F1, three sterols,  $\beta$ -sitosterol,  $\beta$ -sitosteryl acetate, and  $\beta$ -sitosteryl linoleate, one phenyl propanoid, eugenol, one phenolic glycoside, gein, one flavanol, (+)-catechin, and sucrose. The aqueous fraction, obtained by partitioning the MeOH extract with water and chloroform, was the most effective fraction of the extract against all clinical isolates of *H. pylori*. Further investigation of the isolated compounds showed that eugenol was effective against *H. pylori* but gein, diglycosidic eugenol, did not exhibit any activity against *H. pylori*. The subfraction D<sub>4</sub> was the effective fraction which contained tannins. It appeared that tannins were probably the active compounds responsible for the anti-*H. pylori* activity of *G. iranicum*. The aqueous fraction showed a moderate inhibitory activity against both Gram-positive and Gram-negative bacteria. The MIC values indicated that Gram-positive bacteria including *Staphylococcus aureus*, *Staphylococcus epidermidis*, and *Bacillus subtilis* are more susceptible than Gram-negative bacteria including *Escherichia coli* and *Pseudomonas aeruginosa*.

**Key words:** *Geum iranicum*, *Helicobacter pylori*, Eugenol

### Introduction

*Helicobacter pylori* colonizes the stomachs of about 50% of the world's human population. This organism is the main risk factor for peptic ulceration as well as gastric mucosal-associated lymphoid tissue (MALT) lymphoma and gastric adenocarcinoma. The prevention of *H. pylori* colonization could potentially provide primary prevention of the mentioned diseases (Fauci *et al.*, 2008). The common treatments of *H. pylori*

infection, including antibiotics and a proton pump inhibitor, may fail for several reasons. The main reason was found to be *H. pylori* resistance to antibiotics like clarithromycin and metronidazole (Mégraud, 2004). Therefore, the research for new anti-*H. pylori* drugs from plant sources is ongoing (Nariman *et al.*, 2004).

The genus *Geum*, belonging to the Rosaceae family, is a perennial rhizomatous herb with five species in Iran of which *G. iranicum* Khatamsaz is an endemic one (Khatamsaz, 1992; Mozaffarian,

1996). Some *Geum* species are used as medicinal plants in folk medicine (Vollmann and Schultze, 1995; Gruenwald, 2004). The roots of *G. urbanum* and *G. rivale* are employed against diarrhea (Gruenwald, 2004), and *G. japonicum* has been used as diuretic and astringent in traditional Chinese medicine and Japanese folk medicine (Ming *et al.*, 2000). In an Iranian folk remedy, the infusion of the root of *G. iranicum* is employed to treat gastrointestinal disorders like diarrhea, and a decoction of the whole plant is combined with wheat flour and used as a poultice for frostbite (Abutorabi, 2001). Previous studies on extracts of *Geum* species have shown that they can be effective in the treatment of some diseases. A new triterpene acid, 2 $\alpha$ ,19 $\alpha$ -dihydroxy-3-oxo-urs-12-en-28-oic acid, from the extract of *G. japonicum* showed potent inhibitory activity against HIV-1 protease (Xu *et al.*, 2000). In addition, the extract of *G. japonicum* was active against HSV-1 and HSV-2 (herpes simplex virus) (Kurokawa *et al.*, 1995) and CMV (cytomegalo virus) (Yukawa *et al.*, 1996). Some tannins isolated from the extract of this plant showed potent anticoagulant activity (Zeng *et al.*, 1998). Other *Geum* species showed antioxidant (Russo *et al.*, 2005), antimicrobial (Panizzi *et al.*, 2000), and anti-inflammatory (Tunón *et al.*, 1995) effects, respectively. In another study, antimicrobial activity was reported for the extract and essential oil of *Geum kokanicum* that was collected in Iran (Faramarzi *et al.*, 2008). Furthermore, the polar extract of this species showed a potent inhibitory effect on matrix metalloproteinase activity at minimal cytotoxic doses (Khorramizadeh *et al.*, 2006).

A literature review revealed that the anti-*H. pylori* activity of *Geum* species has not been investigated. In the present study we aimed therefore to evaluate the activity of various extracts, sub-fractions, and main components of *G. iranicum* against clinical isolates of *H. pylori* (resistant to metronidazole). Furthermore, the evaluation of the antibacterial activity (against Gram-positive and Gram-negative bacteria) of fractions, together with the isolation and identification of the separated compounds, is reported.

## Material and Methods

### General experimental procedures

Silica gel 60 F<sub>254</sub> pre-coated plates (Merck, Darmstadt, Germany) and anisaldehyde/H<sub>2</sub>SO<sub>4</sub>

reagent followed by heating were used for detecting the compounds. NMR experiments were performed on a Bruker Avance 500 DRX (500 MHz for <sup>1</sup>H and 125 MHz for <sup>13</sup>C) spectrometer (Rheinstetten, Germany). EI-MS spectra were measured on an Agilent Technology (Palo Alto CA, USA) instrument with a 5973 Network mass selective detector (MS model). A CO<sub>2</sub> incubator (Heraeus, Hamburg, Germany) was used for the antibacterial susceptibility tests.

### Plant collection

Roots of *Geum iranicum* were collected from the Gloul Sarani protected area, 75 km north of Shirvan, province of Khorasan-e-Shomali, Iran, at 2460 m above sea level, during the flowering stage in June 2009. A voucher specimen (6714 THE) was deposited at the herbarium of the Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

### Antimicrobial susceptibility test

Three clinical isolates of *H. pylori*, Is.1, Is.2, and Is.3, were obtained from patients with chronic gastritis who had been referred to the Endoscopy Unit at Shariati Hospital, Tehran, Iran. Antral biopsies with positive rapid urease tests were cultured in the microbiology laboratory as described in our previous study (Siavoshi *et al.*, 2010). Antimicrobial susceptibility was tested by the disk diffusion method according to the guidelines of the NCCLS (2006). Serial dilutions of test samples were made in dimethyl sulfoxide (DMSO) (100, 50, 25, 12.5  $\mu$ g/ml). Bacterial suspensions were prepared in normal saline with the turbidity of McFarland standard No. 2 (equivalent to  $6 \cdot 10^8$  cell/ml). The surface of blood agar plates was inoculated with 100  $\mu$ l of each bacterial suspension. Then, plates were dried at room temperature for about 10 min. The sterile blank disks (6 mm in diameter) were placed on the surface of inoculated plates and impregnated with 10  $\mu$ l of each sample dilution. Control plates included blank disks impregnated with 10  $\mu$ l of DMSO. Plates were incubated at 37 °C under microaerobic conditions and examined after 3–5 d. The inhibition zone diameters (IZD) were recorded.

Antibacterial activity of the aqueous fraction was also tested against several Gram-positive and Gram-negative bacteria including *Staphylococcus aureus* ATCC 6538, *Staphylococcus epider-*

*midis* ATCC 12228, *Bacillus subtilis* ATCC 6633, *Escherichia coli* ATCC 8739, and *Pseudomonas aeruginosa* ATCC 9027 by a micro dilution method using 96 U-shaped wells plates (NCCLS, 2006). A 200- $\mu$ l aliquot of stock solutions of the fraction (128 mg/ml) and ciprofloxacin (100  $\mu$ g/ml) as a standard antibiotic compound in Mueller-Hinton broth (MHB) were transferred into the first well in each row and serially diluted by mixing with 100  $\mu$ l of MHB in subsequent wells. Then 100  $\mu$ l of bacterial suspension ( $1 \cdot 10^6$  CFU/ml) were added to each well to reach the final inoculum size of about  $5 \cdot 10^5$  CFU/ml. After 24 h of incubation at 35 °C, the microdilution trays were tested for the absence or presence of visible growth. The endpoint minimum inhibitory concentration (MIC) is the lowest concentration of the fraction at which the test strain does not demonstrate visible growth.

#### Extraction and isolation procedure

Dried roots of *G. iranicum* (1 kg) were cut into small pieces and extracted with EtOAc and MeOH (3  $\times$  4 l for each solvent), successively, by percolation at room temperature to obtain EtOAc (6 g) and MeOH (75 g) extracts. The EtOAc extract was subjected to silica gel column chromatography (CC) (4  $\times$  20 cm) using *n*-hexane/ $\text{CHCl}_3$  (7:3, 3:7 v/v), EtOAc, and MeOH as eluents to give 7 fractions (A–G). Fraction A was further separated by silica gel CC (3  $\times$  20 cm) with *n*-hexane, *n*-hexane/ $\text{CHCl}_3$  (7:3, 3:7 v/v) and  $\text{CHCl}_3$  to give 5 fractions ( $A_1$ – $A_5$ ) of which fraction  $A_3$  contained compound **1** (15 mg). Silica gel CC (2  $\times$  20 cm) was used for separation of fraction B to yield 7 fractions ( $B_1$ – $B_7$ ) with *n*-hexane/ $\text{CHCl}_3$  (7:3, 6:4, 4:6 v/v) and  $\text{CHCl}_3$ . Fraction  $B_2$  was **2** (22 mg). Fraction C was fractionated with *n*-hexane/ $\text{CHCl}_3$  (9:1, 5:5 v/v) by silica gel CC (2  $\times$  20 cm) to give fractions  $C_1$ – $C_5$ ; compound **3** (141 mg) was isolated from fraction  $C_4$ . Compound **4** (5 mg) was obtained from fraction D using silica gel CC (2.5  $\times$  20 cm) with *n*-hexane/EtOAc (8:2 v/v).

The MeOH extract (75 g) was suspended in water and extracted with  $\text{CHCl}_3$  to obtain  $\text{CHCl}_3$  and aqueous fractions. The  $\text{CHCl}_3$  fraction was further chromatographed with *n*-hexane/ $\text{CHCl}_3$  (7:3, 3:7 v/v) and  $\text{CHCl}_3$  to give 6 fractions of which fraction 5 was compound **5** (17 mg). The aqueous portion of the MeOH extract (70 g) was subjected to silica gel CC (10  $\times$  20 cm) with EtOAc, EtOAc/

MeOH (9:1, 7:3, 4:6 v/v) and MeOH to yield 6 fractions (A–F). Fraction A was separated by silica gel CC (2.5  $\times$  20 cm) with  $\text{CHCl}_3$ /MeOH (19:1, 9:1, 8:2 v/v) to yield 5 fractions ( $A_1$ – $A_5$ ). Fraction  $A_4$  was compound **6** (129 mg). Fraction C was subjected to silica gel CC (2.5  $\times$  20 cm) with  $\text{CHCl}_3$ /MeOH (8:2, 7:3 v/v) to give 4 fractions ( $C_1$ – $C_4$ ). Compound **7** (13 mg) was obtained from  $C_2$  using silica gel CC (1.5  $\times$  40 cm) with  $\text{CHCl}_3$ /MeOH (75:25 v/v). Fraction D was chromatographed on a silica gel column (4  $\times$  20 cm) with  $\text{CHCl}_3$ /MeOH (8:2, 6:4 v/v) and MeOH to result in fractions  $D_1$ – $D_4$  of which  $D_2$  was compound **8** (70 mg). Compound **9** (960 mg) was obtained from fraction E using silica gel CC (2.5  $\times$  20 cm) with EtOAc/MeOH (6:4 v/v).

**$\beta$ -Sitosteryl acetate (1):**  $R_f = 0.14$  in *n*-hexane/ $\text{CHCl}_3$  (7:3 v/v). –  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 500 MHz):  $\delta_{\text{H}} = 0.69$  (3H, s, H-18), 0.82 (3H, d,  $J = 6.8$  Hz, H-27), 0.84 (3H, d,  $J = 6.8$  Hz, H-26), 0.86 (3H, t,  $J = 7.3$  Hz, H-29), 0.93 (3H, d,  $J = 6.5$  Hz, H-21), 1.03 (3H, s, H-19), 2.05, (3H, s,  $\text{OCH}_3$ ), 4.61 (1H, m, H-3), 5.38 (1H, brd,  $J = 5$  Hz, H-6). –  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 500 MHz):  $\delta_{\text{C}} = 11.8$  (C-18), 11.9 (C-29), 18.8 (C-21), 19.0 (C-27), 19.3 (C-19), 19.8 (C-26), 21.0 (C-11), 21.4 ( $\text{COOCH}_3$ ), 23.1 (C-28), 24.3 (C-15), 26.1 (C-23), 27.7 (C-2), 28.2 (C-16), 29.1 (C-25), 31.8 (C-8), 31.9 (C-7), 33.9 (C-22), 36.1 (C-20), 36.6 (C-10), 36.9 (C-1), 38.1 (C-4), 39.7 (C-12), 42.3 (C-13), 45.8 (C-24), 50.0 (C-9), 56.0 (C-17), 56.7 (C-14), 73.9 (C-3), 122.6 (C-6), 139.6 (C-5), 170.5 (C=O). – EI-MS:  $m/z$  (%) = 396 [ $\text{M-HOAc}$ ] $^+$  (100), 381 (15), 288 (9), 275 (6), 255 (18), 213 (21).

**$\beta$ -Sitosteryl linoleate (2):**  $R_f = 0.37$  in *n*-hexane/ $\text{CHCl}_3$  (7:3 v/v). –  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 500 MHz):  $\delta_{\text{H}} = 0.68$  (3H, s, H-18), 0.81 (3H, d,  $J = 7$  Hz, H-27), 0.83 (3H, d,  $J = 7$  Hz, H-26), 0.84 (3H, m, H-29), 0.88 (3H, t,  $J = 6.5$  Hz, H-18'), 0.92 (3H, d,  $J = 7$  Hz, H-21), 1.03 (3H, s, H-19), 1.25–1.38 (14H, m, H-4', 5', 6', 7', 15', 16', 17'), 1.59–1.65 (2H, m, H-3'), 2.03–2.08 (4H, m, H-8', 14'), 2.29 (2H, t,  $J = 7.5$  Hz, H-2'), 2.76 (2H, t,  $J = 6.5$  Hz, H-11'), 4.6 (1H, m, H-3), 5.30–5.40 (5H, m, olefinic protons). –  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 500 MHz):  $\delta_{\text{C}} = 11.8$  (C-18), 11.9 (C-29), 14.1 (C-18'), 18.8 (C-21), 19.0 (C-27), 19.3 (C-19), 19.8 (C-26), 21.0 (C-11), 22.7 (C-17'), 23.0 (C-28), 24.3 (C-15), 25.1 (C-3'), 25.6 (C-11'), 26.1 (C-23), 27.2 (C-8', 14'), 27.8 (C-2), 28.3 (C-16), 29.1 (C-25), 29.2 (C-4'), 29.3 (C-5'), 29.4 (C-15'), 29.6 (C-6'), 29.7 (C-7'), 31.6 (C-16'), 31.8

(C-7), 31.9 (C-8), 33.9 (C-22), 34.4 (C-2'), 36.2 (C-20), 36.5 (C-10), 37.0 (C-1), 38.2 (C-4), 39.7 (C-12), 42.3 (C-13), 45.8 (C-24), 50.0 (C-9), 56.0 (C-17), 56.7 (C-14), 73.7 (C-3), 122.6 (C-6), 127.9 (C-10'), 128.0 (C-12'), 130.0 (C-9'), 130.2 (C-13'), 139.7 (5), 173.3 (C=O). – EI-MS:  $m/z$  (%) = 676 [M]<sup>+</sup> (1), 396 (100), 381 (15), 288 (12), 275 (14), 255 (16), 213 (12).

***β*-Sitosterol (3):**  $R_f$  = 0.13 in *n*-hexane/EtOAc (9:1 v/v). – <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta_H$  = 0.68 (3H, s, H-18), 0.79 (3H, d,  $J$  = 6.5 Hz, H-27), 0.82 (3H, d,  $J$  = 6.5 Hz, H-26), 0.83 (3H, t,  $J$  = 7.5 Hz, H-29), 0.91 (3H, d,  $J$  = 6.5 Hz, H-21), 0.99 (3H, s, H-19), 3.5 (1H, m, H-3), 5.3 (1H, brd,  $J$  = 5 Hz, H-6). – <sup>13</sup>C NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta_C$  = 11.8 (C-18), 11.9 (C-29), 18.8 (C-21), 19.0 (C-27), 19.4 (C-19), 19.8 (C-26), 21.1 (C-11), 23.0 (C-28), 24.3 (C-15), 26.0 (C-23), 28.3 (C-16), 29.1 (C-25), 31.6 (C-2), 31.8 (C-7), 31.9 (C-8), 33.9 (C-22), 36.1 (C-20), 36.5 (C-10), 37.2 (C-1), 39.7 (C-12), 42.3 (C-13), 45.8 (C-24), 50.1 (C-9), 56.0 (C-17), 56.8 (C-14), 71.8 (C-3), 121.7 (C-6), 140.7 (C-5). – EI-MS:  $m/z$  (%) = 414 [M]<sup>+</sup> (100), 399 (38), 396 (32), 381 (40), 303 (75), 273 (37), 231 (41), 213 (67).

***Uvaol* (12-ursen-3 $\beta$ ,28-diol) (4):**  $R_f$  = 0.23 in *n*-hexane/EtOAc (8:2 v/v). – <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta_H$  = 0.80 (3H, s, H-25), 0.81 (3H, d,  $J$  = 5.8 Hz, H-30), 0.94 (3H, d, H-29), 0.95 (3H, s, H-24), 0.99 (3H, s, H-26), 1.00 (3H, s, H-27), 1.11 (3H, s, H-23), 3.19 (1H, d,  $J$  = 11 Hz, H-28a), 3.23 (1H, dd,  $J$  = 4.9, 11.3 Hz, H-3), 3.53 (1H, d,  $J$  = 11 Hz, H-28b), 5.14 (1H, t,  $J$  = 3.5, H-12). – <sup>13</sup>C NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta_C$  = 15.6 (C-24), 15.7 (C-25), 16.8 (C-29), 17.3 (C-26), 18.3 (C-6), 21.3 (C-30), 23.3 (C-27), 23.4 (C-11), 26.0 (C-16), 27.2 (C-2), 28.1 (C-23), 29.7 (C-15), 30.6 (C-21), 32.8 (C-7), 35.2 (C-22), 36.8 (C-17), 38.0 (C-10), 38.8 (C-1), 38.8 (C-4), 39.3 (C-19), 39.4 (C-20), 40.0 (C-8), 42.8 (C-14), 47.6 (C-9), 54.0 (C-18), 55.1 (C-5), 69.9 (C-28), 79.0 (C-3), 125.0 (C-12), 138.7 (C-13). – EI-MS:  $m/z$  (%) = 442 [M]<sup>+</sup> (5), 411 (35), 234 (42), 203 (100), 189 (42), 133 (29).

***Eugenol* (5):**  $R_f$  = 0.26 in *n*-hexane/CHCl<sub>3</sub> (3:7 v/v). – <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta_H$  = 3.32 (2H, d,  $J$  = 6.65 Hz, H-7), 3.87 (3H, s, OCH<sub>3</sub>), 5.05 (2H, m, H-9), 5.48 (1H, brs, OH), 5.95 (1H, m, H-8), 6.69 (2H, m, H-3 and H-5), 6.84 (1H, d,  $J$  = 8.5 Hz, H-6). – <sup>13</sup>C NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta_C$  = 39.9 (C-7), 55.8 (OCH<sub>3</sub>), 111.1 (C-3), 114.2 (C-6), 115.5 (C-9), 121.2 (C-5), 131.9 (C-4), 137.8 (C-8), 143.9 (C-1), 146.4 (C-2).

***Catechin* (6):**  $R_f$  = 0.37 in CHCl<sub>3</sub>/MeOH (8:2 v/v). – <sup>1</sup>H NMR (CD<sub>3</sub>OD, 500 MHz):  $\delta_H$  = 2.51 (1H, dd,  $J$  = 16.1, 8.2 Hz, H-4a), 2.86 (1H, dd,  $J$  = 16.1, 5.4 Hz, H-4b), 3.97 (1H, m, H-3), 4.57 (1H, d,  $J$  = 7.5 Hz, H-2), 5.86 (1H, d,  $J$  = 2.2 Hz, H-8), 5.93 (1H, d,  $J$  = 2.2 Hz, H-6), 6.72 (1H, dd,  $J$  = 8.1, 2 Hz, H-6'), 6.76 (1H, d,  $J$  = 8.1, H-5'), 6.84 (1H, d,  $J$  = 2 Hz, H-2'). – <sup>13</sup>C NMR (CD<sub>3</sub>OD, 500 MHz):  $\delta_C$  = 28.4 (C-4), 68.6 (C-3), 82.7 (C-2), 95.4 (C-8), 96.2 (C-6), 100.7 (C-10), 115.1 (C-2'), 116.0 (C-5'), 119.9 (C-6'), 132.0 (C-1'), 146.1 (C-3'), 146.1 (C-4'), 156.8 (C-9), 157.4 (C-5), 157.6 (C-7).

***Niga-ichigoside F1* (2 $\alpha$ ,3 $\beta$ ,19 $\alpha$ ,23-tetrahydroxyurs-12-en-28-oic acid  $\beta$ -D-glucopyranosyl ester) (7):**  $R_f$  = 0.47 in CHCl<sub>3</sub>/MeOH (75:25 v/v). – <sup>1</sup>H NMR (CD<sub>3</sub>OD, 500 MHz):  $\delta_H$  = 0.7 (3H, s, H-24), 0.78 (3H, s, H-26), 0.93 (3H, d,  $J$  = 6.5 Hz, H-30), 1.04 (3H, s, H-25), 1.21 (3H, s, H-29), 1.34 (3H, s, H-27), 2.52 (1H, s, H-18), 3.25 (1H, d,  $J$  = 11 Hz, H-23a), 3.49 (1H, d,  $J$  = 11 Hz, H-23b), 3.67 (1H, m, H-2), 3.35–3.82 (5H, H<sub>Glc</sub>-2–6), 5.31 (2H, d,  $J$  = 8.1 Hz, H<sub>Glc</sub>-1, H-12). – <sup>13</sup>C NMR (CD<sub>3</sub>OD, 500 MHz):  $\delta_C$  = 13.9 (C-24), 16.6 (C-30), 17.6 (C-26), 17.7 (C-25), 19.2 (C-6), 24.7 (C-27), 24.8 (C-11), 26.5 (C-16), 27.1 (C-29), 27.2 (C-21), 29.6 (C-15), 33.5 (C-7), 38.3 (C-22), 38.9 (C-10), 40.8 (C-8), 42.8 (C-14), 42.9 (C-20), 44.1 (C-4), 48.0 (C-1), 48.2 (C-9), 48.4 (C-5), 54.9 (C-18), 66.4 (C-23), 69.7 (C-2), 73.6 (C-19), 78.3 (C-3), 129.7 (C-12), 139.5 (C-13), 178.5 (C=O); glucose: 62.4 (C-6'), 71.1 (C-4'), 73.8 (C-2'), 78.3 (C-5'), 78.5 (C-3'), 95.8 (C-1'). – EI-MS:  $m/z$  (%) = 504 [M–C<sub>6</sub>H<sub>10</sub>O<sub>5</sub>] (4), 426 (23), 344 (100), 264 (15), 246 (18), 239 (22), 219 (17), 201 (34), 164 (72).

***Gein* (eugenyl vicianoside) (8):**  $R_f$  = 0.2 in CHCl<sub>3</sub>/MeOH (8:2 v/v). – <sup>1</sup>H NMR, <sup>13</sup>C NMR, and HMBC (CD<sub>3</sub>OD, 500 MHz): see Table I.

***Sucrose* (9):**  $R_f$  = 0.28 in EtOAc/MeOH (6:4 v/v). – <sup>1</sup>H NMR (D<sub>2</sub>O, 500 MHz):  $\delta_H$  = 3.31 (1H, t,  $J$  = 9.5 Hz, H<sub>Glc</sub>-4), 3.4 (1H, dd,  $J$  = 10, 3.8 Hz, H<sub>Glc</sub>-2), 3.51 (2H, s, H<sub>Fru</sub>-1), 3.59 (1H, t,  $J$  = 9.5 Hz, H<sub>Glc</sub>-3), 3.66 (4H, m, H<sub>Glc</sub>-6 and H<sub>Fru</sub>-6), 3.69 (1H, m, H<sub>Glc</sub>-5), 3.72 (1H, m, H<sub>Fru</sub>-5), 3.89 (1H, t,  $J$  = 8.5 Hz, H<sub>Fru</sub>-4), 4.04 (1H, d,  $J$  = 8.7 Hz, H<sub>Fru</sub>-3), 5.25 (1H, d,  $J$  = 3.8 Hz, H<sub>Glc</sub>-1). – <sup>13</sup>C NMR (D<sub>2</sub>O, 500 MHz):  $\delta_C$  = 60.1 (C<sub>Glc</sub>-6), 61.3 (C<sub>Fru</sub>-1), 62.3 (C<sub>Fru</sub>-6), 69.2 (C<sub>Glc</sub>-4), 71.0 (C<sub>Glc</sub>-2), 72.4 (C<sub>Glc</sub>-5), 72.5 (C<sub>Glc</sub>-3), 73.9 (C<sub>Fru</sub>-4), 76.3 (C<sub>Fru</sub>-3), 81.3 (C<sub>Fru</sub>-5), 92.1 (C<sub>Glc</sub>-1), 103.6 (C<sub>Fru</sub>-2).



Table I. NMR data of compound **8** in CD<sub>3</sub>OD.

Carbon No.	<sup>13</sup> C NMR (ppm)	<sup>1</sup> H NMR (ppm)	HMBC
1	146.1		H-3, H-5, H-6, H-1'
2	150.7		OCH <sub>3</sub> , H-3, H-6
3	114.0	6.82 (d, J = 2 Hz, 1H)	H-5, H-7
4	136.4		H-3, H-5, H-6, H-7, H-8
5	122.2	6.76 (dd, J = 8.2, 2 Hz, 1H)	H-3, H-7
6	118.3	7.11 (d, J = 8.1 Hz, 1H)	
7	40.7	3.33 (d, J = 6.6 Hz, 2H)	H-3, H-5, H-8, H-9
8	139.0	5.95 (m, 1H)	H-7
9	115.8	5.04 (m, 2H)	H-7
OMe	56.6	3.84 (s, 3H)	
Glc			
1'	102.7	4.86 (d, J = 7.1 Hz, 1H)	
2'	74.9	3.48 (m, 1H)	
3'	77.6	3.46 (m, 1H)	H-4'
4'	71.4	3.40 (m, 1H)	
5'	77.3	3.58 (m, 1H)	H-4', H-6'
6'	69.1	3.75 (m, 1H)	H-4', H-1''
		4.08 (dd, J = 11.5, 2.1 Hz, 1H)	
Ara			
1''	104.7	4.28 (d, J = 6.8 Hz, 1H)	H-6'a, H- 6'b, H-2'', H-5''a, H-5''b
2''	72.4	3.56 (m, 1H)	
3''	74.1	3.48 (m, 1H)	H-1'', H-2'', H-4''
4''	69.4	3.76 (m, 1H)	H-5''a, H-5''b
5''	66.6	3.44 (m, 1H)	H-1''
		3.81 (dd, J = 12.3, 3.3 Hz, 1H)	

## Results

The inhibition zone diameters (IZD) of test samples and antibiotics against *H. pylori* are summarized in Tables II and III. No inhibition zone was observed for DMSO in control plates. The MIC values of the aqueous fraction and ciprofloxacin (as a positive control) against several Gram-positive and Gram-negative bacteria are shown in Table IV.

From the EtOAc and MeOH extracts of the roots, nine compounds including two triterpenoids, uvaol (**4**) (Mahato and Kundu, 1994) and niga-ichigoside F1 (**7**) (Bowen-Forbes *et al.*, 2009), three sterols,  $\beta$ -sitosterol (**3**),  $\beta$ -sitosterol acetate (**1**) (Goat and Akihisa, 1997), and  $\beta$ -sitosterol linoleate (**2**) (Huh *et al.*, 2010; Dyas *et al.*, 1991), one phenyl propanoid, eugenol (**5**), one phenolic glycoside, gein (**8**) (Takeda *et al.*, 1998; Shimoda *et al.*, 2007; Shigenaga *et al.*, 1985), one flavanol, (+)-catechin (**6**) (Banavides *et al.*, 2006), and sucrose (**9**) (Agrawal, 1992) were isolated by column chromatography and identified by comparison of their spectroscopic data with those in the literature (Fig. 1). Spectroscopic data such as <sup>1</sup>H

and <sup>13</sup>C NMR, HMQC, HMBC, <sup>1</sup>H-<sup>1</sup>H COSY and EI-MS were employed for identification of the isolated compounds. In the previous study, the NMR data of gein were reported in CDCl<sub>3</sub> and pyridine-d<sub>5</sub> (Shigenaga *et al.*, 1985). To the best of our knowledge, there is no report on the 2D-NMR correlations of this compound, so that this is the first report on the NMR data of gein in CD<sub>3</sub>OD and HSQC and HMBC correlations (Table I and Fig. 2).

## Discussion

The MeOH extract of *G. iranicum* was considered an effective extract against one of the clinical isolates of *H. pylori* which was resistant to metronidazole. As shown in Table II, the chloroform fraction, obtained from the MeOH extract, was not effective against *H. pylori*, but the aqueous fraction showed a potent activity (Table II). Subfractions of the aqueous part were evaluated for their antibacterial activity against all isolates. Fraction D was the only one that displayed antibacterial activity (MIC = 25  $\mu$ g/ml). Therefore, the fractions obtained from D fractionation were

Table II. Inhibition zone diameters (mm) of some extracts of *G. iranicum*.

Sample	Mean inhibition zone diameter [mm] <sup>a</sup>											
	100 µg/ml			50 µg/ml			25 µg/ml			12.5 µg/ml		
	Is.1 <sup>b</sup>	Is.2	Is.3	Is.1	Is.2	Is.3	Is.1	Is.2	Is.3	Is.1	Is.2	Is.3
Ethyl acetate extract	-	-	-	-	-	-	-	-	-	-	-	-
Methanol extract	15±0.5	-	-	-	-	-	-	-	-	-	-	-
Chloroform fraction	-	-	-	-	-	-	-	-	-	-	-	-
Aqueous fraction	35±0.5	30±0.5	24±0.5	28±0	26±0.5	18±0.25	24±0.57	24±0.5	16±0	20±0.5	19±0.5	14±0
Fraction D	22±0.5	21±0.25	12±0.5	15±0.5	12±0.5	10±0.5	12±0	10±0.5	-	-	-	-
Fraction D <sub>4</sub>	17±0.25	16±0.5	20±0	12±0.57	12±0.5	10±0.5	10±0.5	10±0.28	-	10±0.25	9±0	-
Eugenol	20±0.5	22±0.28	10±0.5	-	-	-	-	-	-	-	-	-
Catechin	-	-	-	-	-	-	-	-	-	-	-	-
Niga-ichigoside F1	-	-	-	-	-	-	-	-	-	-	-	-
Gein	-	-	-	-	-	-	-	-	-	-	-	-

<sup>a</sup> The results are shown as mean ± SD (*n* = 3).<sup>b</sup> Is, clinical isolate of *H. pylori*.Table III. Inhibition zone diameters (mm) of some antibiotics against clinical isolates of *H. pylori*.

Antibiotic [µg/ml]	Inhibition zone diameter [mm]		
	Is.1 <sup>a</sup>	Is.2	Is.3
Furazolidone (MIC 0.5 µg/ml)			
2	34	19	25
1	22	15	21
0.5	11	10	18
0.25	-	-	13
Tetracycline (MIC 2 µg/ml)			
4	20	-	-
2	13	-	-
1	-	-	-
0.5	-	-	-
Amoxicillin (MIC 0.5 µg/ml)			
2	40	30	36
1	30	24	25
0.5	20	12	15
0.25	11	-	10
Clarithromycin (MIC 2 µg/ml)			
4	-	35	33
2	-	28	27
1	-	24	24
0.5	-	21	19
Metronidazole (MIC 8 µg/ml)			
32	-	-	-
16	-	-	-
8	-	-	-
4	-	-	-

<sup>a</sup> Is, clinical isolate of *H. pylori*.Table IV. Minimum inhibitory concentrations of the aqueous fraction of *G. iranicum* against several Gram-positive and Gram-negative bacteria.

Bacterial strain <sup>a</sup>	Minimum inhibitory concentration	
	Aqueous fraction [mg/ml]	Ciprofloxacin [µg/ml]
<i>S. aureus</i>	16	0.19
<i>S. epidermidis</i>	16	0.39
<i>B. subtilis</i>	16	0.19
<i>E. coli</i>	32	0.013
<i>P. aeruginosa</i>	32	0.39

<sup>a</sup> The bacterial strains are *Staphylococcus aureus* ATCC 6538, *Staphylococcus epidermidis* ATCC 12228, *Bacillus subtilis* ATCC 6633, *Escherichia coli* ATCC 8739, *Pseudomonas aeruginosa* ATCC 9027.

evaluated again and resulted in one active fraction D<sub>4</sub> (Table II). Finally, the isolated compounds from the chloroform and aqueous fractions (eugenol, gein, catechin, and niga-ichigoside F1) were examined for anti-*H. pylori* activity. Among the tested compounds, eugenol (**5**), isolated from the chloroform fraction, showed an antibacterial effect at a concentration of 100 µg/ml with inhibition zones of 20, 22, and 10 mm against the isolates 1, 2, and 3 respectively. Eugenol is a major compound in the root oil of *G. iranicum* (Shahani *et al.*, 2011) and is employed as a flavour-





Fig. 1. Chemical structures of the isolated compounds.

Fig. 2. HMBC correlations of compound **8** (H $\rightarrow$ C).

ing agent in cosmetics and food products, as well as a cement material in dentistry (Atsumi *et al.*, 2005). Furthermore, eugenol has been found to exhibit a broad range of biological activities including antibacterial (Devi *et al.*, 2010), antifungal (Campaniello *et al.*, 2010), antiviral (Benencia and Courreges, 2000), antioxidant (Atsumi *et*

*al.*, 2005), anti-inflammatory (Yogalakshmi *et al.*, 2010), anti nociceptive (Daniel *et al.*, 2009), and antidepressant activity (Tao *et al.*, 2005). A literature review shows that the minimal bactericidal concentration (MBC) of eugenol (obtained from essential oils) was 100  $\mu$ g/ml against one strain of *H. pylori*, which had been isolated from a pa-

tient with non-ulcer dyspepsia (Bergonzelli *et al.*, 2003). Elsewhere it was reported that eugenol (commercial preparation) inhibited the growth of 30 strains of *H. pylori* at a concentration of 2 µg/ml (Ali *et al.*, 2005). Our antibacterial data for eugenol agree with the results reported by Bergonzelli *et al.* (2003).

Diglycosylated eugenol, named gein (**8**), produced no inhibition zone. Gein has been isolated from other *Geum* species (Shigenaga *et al.*, 1985), and no biological activity has been reported for this compound. It seems that glycosylation of eugenol causes a decrease in anti-*H. pylori* activity. Also other purified compounds like catechin (**6**) and niga-ichigoside F1 (**7**) did not display any antibacterial activity at all concentrations.

Fraction D<sub>4</sub> exhibited antibacterial activity as shown in Table II. Further investigation of fraction D<sub>4</sub> indicated that this fraction can precipitate a solution of gelatin (1%), containing sodium chloride (10%), and give a blue-black precipitate with ferric chloride. Therefore, this fraction should include polar compounds, especially hydrolysable tannins (Evans, 2009). There is a report in the literature on the antibacterial activity of hydrolysable tannins derived from medicinal plants against *H. pylori* (Funatogawa *et al.*, 2004). For this reason, it seems that tannins from *G. iranicum* might

be one of the important groups of compounds active against *H. pylori*.

The aqueous fraction exhibited a moderate inhibitory activity against both Gram-positive and Gram-negative bacteria. The Gram-positive bacteria were inhibited at 16 mg/ml, while Gram-negative bacteria were inhibited at about 32 mg/ml.

In conclusion, considering the increasing resistance of *H. pylori* to antibiotics like metronidazole and clarithromycin, there is great interest in finding new drugs from natural sources. The results of this study show that *G. iranicum* has a significant antibacterial activity against resistant clinical isolates of *H. pylori*. Eugenol is one of the effective compounds, whereas other purified compounds (like gein, catechin, and niga-ichigoside F1) were not effective. Finally, the tannin-containing fraction of *G. iranicum* showed considerable anti-*H. pylori* activity. Further investigation is required to purify the active tannins from this plant.

#### Acknowledgement

This research has been supported by a grant from Tehran University of Medical Sciences and Health Services. The authors thank Mr. Yousef Ajani from the Institute of Medicinal Plants for plant collection and identification.

- Abutorabi H. (2001), Ethnobotanical and phytochemical study on the plants of Rouin region. Pharm. D. Thesis. Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
- Agrawal P. K. (1992), NMR spectroscopy in the structural elucidation of oligosaccharides and glycosides. *Phytochemistry* **31**, 3307–3330.
- Ali S. M., Khan A. A., Ahmed I., Musaddiq M., Ahmed K. S., Polasa H., Venkateswar Rao L., Habibullah C. M., Sechi L. A., and Ahmed N. (2005), Antimicrobial activities of eugenol and cinnamaldehyde against the human gastric pathogen *Helicobacter pylori*. *Ann. Clin. Microbiol. Antimicrob.* **4**, 1–7.
- Atsumi T., Fujisawa S., and Tonosaki K. (2005), A comparative study of the antioxidant/prooxidant activities of eugenol and isoeugenol with various concentrations and oxidation conditions. *Toxicol. In Vitro* **19**, 1025–1033.
- Banavides A., Montoro P., Bassarello C., Piacente S., and Pizza C. (2006), Catechin derivatives in *Jatropha macrantha* stems: characterization and LC/ESI/MS/MS qualitative-quantitative analysis. *J. Pharm. Biomed. Anal.* **40**, 639–647.
- Benencia F. and Courreges M. C. (2000), *In vitro* and *in vivo* activity of eugenol on human herpes virus. *Phytother. Res.* **14**, 495–500.
- Bergonzelli G. E., Donnicola D., Porta N., and Corthésy-Theulaz I. E. (2003), Essential oils as components of a diet-based approach to management of *Helicobacter* infection. *Antimicrob. Agents Chemother.* **47**, 3240–3246.
- Bowen-Forbes C. S., Mulabagal V., Liu Y., and Nair M. G. (2009), Ursolic acid analogues: non-phenolic functional food components in Jamaican raspberry fruits. *Food Chem.* **116**, 633–637.
- Campaniello D., Corbo M. R., and Sinigaglia M. (2010), Activity of eugenol against *Penicillium*, *Aspergillus* and *Fusarium* species. *J. Food Prot.* **73**, 1124–1128.
- Daniel A. N., Sartoretto S. M., Schmidt G., Caparroz-Assef S. M., Bersani-Amado C. A., and Cuman R. K. N. (2009), Anti-inflammatory and antinociceptive activities of eugenol essential oil in experimental animal models. *Braz. J. Pharmacog.* **19**, 212–217.
- Devi K. P., Nisha S. A., Sakthivel R., and Pandian S. K. (2010), Eugenol (an essential oil of clove) acts as an antibacterial agent against *Salmonella typhi* by dis-



- rupting the cellular membrane. *J. Ethnopharmacol.* **130**, 107–115.
- Dyas L., Prescott M. C., Evershed R. P., and Goad L. J. (1991), Steryl esters in a cell suspension culture of celery (*Apium graveolens*). *Lipids* **26**, 536.
- Evans W. C. (2009), *Trease and Evans Pharmacognosy*, 16<sup>th</sup> ed. Saunders Elsevier, Edinburgh.
- Faramarzi M. A., Moghimi M., Monsef-Esfahani H. R., Shahverdi A. R., and Khodaei S. (2008), Chemical composition and antimicrobial activity of essential oils from *Geum kokanicum*. *Chem. Nat. Compd.* **44**, 811–813.
- Fauci A. S., Branuwald E., Kasper D. L., Hauser S. L., Longo D. L., Jameson J. L., and Loscalzo J. (2008), In: *Harrison's Principles of Internal Medicine*, 17<sup>th</sup> ed. Mc Graw-Hill, New York.
- Funatogawa K., Hayashi S., Shimomura H., Yoshida T., Hatano T., Ito H., and Hirai Y. (2004), Antibacterial activity of hydrolysable tannins derived from medicinal plants against *Helicobacter pylori*. *Microbiol. Immunol.* **48**, 251–261.
- Goad L. J. and Akihisa T. (1997), *Analysis of Sterols*. Blackie Academic & Professional, London.
- Gruenewald J. (2004), *PDR for Herbal Medicine*. Thomson PDR, Montvale.
- Huh S., Kim Y. S., Jung E., Lim J., Jung K. S., Kim M. O., Lee J., and Park D. (2010), Melanogenesis inhibitory effect of fatty acid alkyl esters isolated from *Oxalis triangularis*. *Biol. Pharm. Bull.* **33**, 1242–1245.
- Khatamsaz K. (1992), *Flora of Iran*, No. 6: Rosaceae. Research Institute of Forest and Rangelands, Karaj.
- Khorramzadeh M. R., Shahverdi A. R., Saadat F., and Monsef-Esfahani H. R. (2006), Inhibitory effect of *Geum kokanicum* roots on matrix metalloproteinases expression. *Pharmaceut. Biol.* **44**, 266–270.
- Kurokawa M., Nagasaka K., Hirabayashi T., Uyama S., Sato H., Kageyama T., Kadota S., Ohshima H., Hozumi T., and Namba T. (1995), Efficacy of traditional herbal medicines in combination with acyclovir against herpes simplex virus type 1 infection *in vitro* and *in vivo*. *Antiviral Res.* **27**, 19–37.
- Mahato S. B. and Kundu A. P. (1994), <sup>13</sup>C-NMR spectra of pentacyclic triterpenoids – complication and salient features. *Phytochemistry* **37**, 1517–1573.
- Mégraud F. (2004), *H. pylori* antibiotic resistance: prevalence, importance, and advances in testing. *Gut* **53**, 1374–1384.
- Ming D. S., Xu H. X., Dong H., and But P. P. H. (2000), Research progress in chemical constituents and biological activities of *Geum* species. *Acta Pharm. Sin.* **35**, 552–558.
- Mozaffarian V. (1996), *A Dictionary of Iranian Plant Names*. Farhang Moaser Publication, Tehran.
- Nariman F., Eftekhari F., Habibi Z., and Falsafi T. (2004), Anti-*Helicobacter pylori* activities of six Iranian plants. *Helicobacter* **9**, 146–151.
- NCCLS (2006), *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically*. Approved Standard M7-A7, 7<sup>th</sup> ed. National Committee for Clinical Laboratory Standards, Wayne, PA, USA.
- Panizzi L., Catalano S., Miarelli C., Cioni P. L., and Campeol E. (2000), *In vitro* antimicrobial activity of extracts and isolated constituents of *Geum rivale*. *Phytother. Res.* **14**, 561–563.
- Russo A., Cardile V., Lombardo L., Vanella A., and Garbarino J. A. (2005), Antioxidant activity and antiproliferative action of methanolic extract of *Geum quellyon* sweet roots in human tumor cell lines. *J. Ethnopharmacol.* **100**, 323–332.
- Shahani S., Monsef-Esfahani H. R., Hajiaghvaei R., and Gohari A. R. (2011), Chemical composition of essential oil and hydrolate of *Geum iranicum* Khatamsaz. *J. Essent. Oil Res.* **23**, 29–33.
- Shigenaga S., Kouno I., and Kawano N. (1985), Triterpenoids and glycosides from *Geum japonicum*. *Phytochemistry* **24**, 115–118.
- Shimoda K., Kwon S., Utsuki A., Ohiwa S., Katsuragi H., Yonemoto N., Hamada H., and Hamada H. (2007), Glycosylation of capsaicin and 8-nordihydrocapsaicin by cultured cells of *Catharanthus roseus*. *Phytochemistry* **68**, 1391–1396.
- Siavoshi F., Saniee P., Latifi-Navid S., Massarrat S., and Sheykholeslami A. (2010), Increase in resistance rates of *H. pylori* isolates to metronidazole and tetracycline – comparison of three 3-year studies. *Arch. Iran Med.* **13**, 177–187.
- Takeda Y., Ooiso Y., Masuda T., Honda G., Otsuka H., Sezik E., and Yesilada E. (1998), Iridoid and eugenol glycosides from *Nepeta cadmea*. *Phytochemistry* **49**, 787–791.
- Tao G., Irie Y., Li D. J., and Keung W. M. (2005), Eugenol and its structural analogs inhibit monoamine oxidase A and exhibit antidepressant-like activity. *Bioorg. Med. Chem.* **13**, 4777–4788.
- Tunón H., Olavsdotter C., and Bohlin L. (1995), Evaluation of anti-inflammatory activity of some Swedish medicinal plants. Inhibition of prostaglandin biosynthesis and PAF-induced exocytosis. *J. Ethnopharmacol.* **48**, 61–76.
- Vollmann C. and Schultze W. (1995), Composition of the root essential oils of several *Geum* species and related members of the subtribus Geinae (Rosaceae). *Flavour Fragr.* **10**, 173–178.
- Xu H. X., Ming D. S., Dong H., and But P. P. H. (2000), A new anti-HIV triterpene from *Geum japonicum*. *Chem. Pharm. Bull.* **48**, 1367–1369.
- Yogalakshmi B., Viswanathan P., and Anuradha C. V. (2010), Investigation of antioxidant, anti-inflammatory and DNA-protective properties of eugenol in thioacetamide-induced liver injury in rats. *Toxicology* **268**, 204–212.
- Yukawa T. A., Kurokawa M., Sato H., Yoshida Y., Kageyama S., Hasegawa T., Namba T., Imakita M., Hozumi T., and Shiraki K. (1996), Prophylactic treatment of cytomegalovirus infection with traditional herbs. *Antiviral Res.* **32**, 63–70.
- Zeng F. Q., Xu H. X., Sim K. Y., Gunsekera R. M., and Cheu S. X. (1998), The anticoagulant effects of *Geum japonicum* extract and its constituents. *Phytother. Res.* **12**, 146–148.